How will India’s leading drugmaker handle legal setbacks, volatile market trends, and competition in generics and specialty products?

Welcome to the Sun Pharma Stock Liveblog, your go-to platform for real-time updates and analysis on a top-performing stock.

The company’s revenue from operations saw a significant decline of 39%, dropping to ₹12.9 Crore from ₹21.2 Crore in the ...

Stay up-to-date with the Sun Pharma Stock Liveblog, your comprehensive source for real-time updates and detailed analysis on ...

Despite winning an alopecia areata approval for its drug Leqselvi in July, Sun Pharma will have to wait a while longer to ...

Thirty out of the 41 analysts tracking the company have a 'buy' rating on the stock, seven suggest a 'hold' and four have a ...

Incyte filed a lawsuit to try to block the launch of Leqselvi, claiming that the drug infringed a US patent (No. 9,662,335) ...

Mumbai: Indoco Remedies has announced the appointment of Vaibhav Sinha as Senior Management Personnel designated as Vice ...

Shares of Sun Pharmaceutical Industries declined five per cent to Rs 1,766.15 in early trade on the BSE on Monday following a ...

In the worst-case scenario, an unfavourable judgment would prevent Sun Pharma from launching Leqselvi until the patent expires, delaying its market entry.

Sun Pharmaceutical Industries is likely to attract attention on Monday (November 4) following a recent US court ruling that ...

Pharma giant, Sun Pharmaceutical's launch of its specialty drug Leqselvi in the U.S. market is in limbo as the U.S. District Court in New Jersey has issued a preliminary injunction.